AstraZeneca details growth strategy
AstraZeneca plc (LSE:AZN; NYSE:AZN) said at an investor day on Thursday that it is aiming to double its Phase III pipeline by 2016 and will focus small and large molecule R&D on three core areas: respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; and cancer. Pascal Soriot, who took over as CEO in October, said the pharma is aiming to create a portfolio with specialty care products to balance AstraZeneca's expertise in primary care.
AstraZeneca also is aiming to return to growth by focusing its investment and resources on five areas, including emerging markets and Japan. The pharma said it believes it can "significantly exceed" consensus estimates for 2018 revenues of $21.5 billion (see BioCentury, Nov. 5, 2012). ...